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Anita Boratkó, Pál Gergely and Csilla Csortos*Abstract
Background: RACK1, receptor for activated protein kinase C, serves as an anchor in multiple signaling pathways.
TIMAP, TGF-β inhibited membrane-associated protein, is most abundant in endothelial cells with a regulatory effect
on the endothelial barrier function. The interaction of TIMAP with protein phosphatase 1 (PP1cδ) was characterized,
yet little is known about its further partners.
Results: We identified two novel interacting partners of RACK1, namely, TGF-β inhibited membrane-associated
protein, TIMAP, and farnesyl transferase. TIMAP is most abundant in endothelial cells where it is involved in the
regulation of the barrier function. WD1-4 repeats of RACK1 were identified as critical regions of the interaction both
with TIMAP and farnesyl transferase. Phosphorylation of TIMAP by activation of the cAMP/PKA pathway reduced the
amount of TIMAP-RACK1 complex and enhanced translocation of TIMAP to the cell membrane in vascular
endothelial cells. However, both membrane localization of TIMAP and transendothelial resistance were attenuated
after RACK1 depletion. Farnesyl transferase, the enzyme responsible for prenylation and consequent membrane
localization of TIMAP, is present in the RACK1-TIMAP complex in control cells, but it does not co-immunoprecipitate
with TIMAP after RACK1 depletion.
Conclusions: Transient parallel linkage of TIMAP and farnesyl transferase to RACK1 could ensure prenylation and
transport of TIMAP to the plasma membrane where it may attend in maintaining the endothelial barrier as a
phosphatase regulator.
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The vascular endothelium functions as a semi-permeable
barrier between blood and the interstitium. Endothelial
cell (EC) barrier regulation is under intense investigation,
since EC barrier dysfunction is a well-known feature of
acute lung injury (ALI) and its more severe form, acute
respiratory distress syndrome (ARDS) [1]. Barrier enhan-
cing or protecting processes are not explored in details
yet, however, several studies indicate the significance of
dephosphorylation of key cytoskeletal/membrane asso-
ciated targets by specific protein phosphatases [2].
TIMAP (TGF-β inhibited membrane-associated protein)
protein has been considered as a member of the MYPT
(myosin phosphatase targeting) family of the regulatory
subunits of protein phosphatase 1 (PP1) based on its
structural features [3]. TIMAP and MYPT3 are the most* Correspondence: csortos@med.unideb.hu
Department of Medical Chemistry, University of Debrecen Medical and
Health Science Center, Egyetem tér 1, Debrecen, H 4032, Hungary
© 2013 Boratkó et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the orclosely related members within the family. Both proteins
contain ankyrin repeats, a PP1 catalytic subunit (PP1c)
binding motif and a C-terminal prenylation motif; the
latter one mediates their association with the plasma
membrane [3]. A bipartite nuclear localization signal
(NLS) is also present in TIMAP; accordingly, it was
detected in the nucleus of vascular endothelial cells [4],
but its significance is not known yet. In view of the fact
that TIMAP mRNA synthesis is down-regulated by
TGF-β1 [3], the transcriptional repression of TIMAP
could be an important component of the TGF-β1 path-
way, as well as apoptosis and endothelial barrier integrity.
TIMAP is most abundant in endothelial cells, yet little is
known about its exact function and its interacting part-
ners. We have demonstrated specific protein-protein
interaction between TIMAP and PP1cδ (a.k.a. PP1cβ);
and the effect of TIMAP phosphorylation on this inter-
action was also characterized [4,5]. Studies made on
TIMAP-depleted human pulmonary artery endotheliall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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positive regulatory effect on the endothelial barrier func-
tion. In the absence of TIMAP the effects of barrier func-
tion compromising agents (thrombin and nocodazole)
were enhanced and the effects of barrier function pro-
tecting agents (sphingosine-1-phosphate and ATP) were
attenuated [4]. Our work revealed that the ERM (ezrin-
radixin-moesin) proteins, which connect actin filaments
to the plasma membrane, are interacting protein partners
for TIMAP and they were identified as TIMAP-PP1c
substrates [4,5]. We also showed the involvement of
TIMAP in PKA-mediated ERM dephosphorylation as
part of endothelial cell barrier protection by TIMAP
[4,5].
The non-integrin laminin receptor 1 (LAMR1), which
is involved in the regulation of cell motility, was also
described to interact with TIMAP. They co-localize at
the plasma membrane of endothelial cells and TIMAP
regulates the dephosphorylation of LAMR1 by PP1c [6].
Several potential TIMAP-binding proteins were identi-
fied by bacterial two-hybrid screening. Among them are
the cysteine and glycine rich protein 1 and the eukaryotic
translation elongation factor 2, which are both involved
in the organization of the actin cytoskeleton. However,
these interactions in mammalian cells have not been veri-
fied yet [7].
In a hunt for new TIMAP-binding partners, we found
that RACK1 (receptor of activated kinase 1, a.k.a. guan-
ine nucleotide-binding protein subunit beta-2-like 1,
GNB2L1, or human lung cancer oncogene 7 protein)
interacts with TIMAP in pulmonary artery endothelial
cells. RACK1 is a scaffolding/anchoring protein that con-
tains seven Trp-Asp (WD) repeats predicted to form a
seven-bladed propeller structure. Therefore RACK1 is
capable to interact simultaneously with several signaling
molecules [8], suggesting the possibility of multiple pro-
tein interaction surfaces. It has been named by its bind-
ing to activated PKC [9], but several other interacting
partners were also identified [10-14]. Upon activation of
PKC with PMA, RACK1 co-localizes with the Src tyro-
sine kinase at the plasma membrane [15]; and RACK1
functions as a substrate, as well as a binding partner and
inhibitor of the kinase [15,16]. Recently, it was also
demonstrated that RACK1 is a core component of the
eukaryotic 40S ribosomal subunit [17-19], localized on
the head region close to the mRNA exit channel, suggest-
ing a physical link between the eukaryotic ribosome and
cell signaling pathways in vivo [20]. In accord with its
structural features, all these recent findings imply the in-
volvement of RACK1 in numerous signaling pathways.
Here, we report and characterize the interaction of
RACK1 with TIMAP, a protein involved in the regulation
of endothelial barrier function, and with farnesyl trans-
ferase, the enzyme catalyzing prenylation of TIMAP inendothelial cells. We show the significance of these inter-
actions in the prenylation of TIMAP, consequently in its
traffic to the plasma membrane.
Results
RACK1 binds TIMAP-PP1c complex in endothelial cells
To identify new interacting partners of TIMAP in endothe-
lial cells, GST pull-down assay was performed. BPAEC lys-
ate was incubated with GST-tagged recombinant full length
TIMAP protein immobilized on glutathione Sepharose.
GST protein incubated with the cell lysate and GST-TIMAP
incubated with the lysis buffer were used as negative con-
trols. After the necessary washing steps the eluted proteins
were separated on SDS-PAGE stained with BlueSilver solu-
tion and the pattern of the protein bands in the three sam-
ples were compared. An extra band at about 34 kDa was
identified in the sample of GST-TIMAP incubated with
BPAEC lysate (Additional file 1: Figure S1). It was cut from
the gel and was further analyzed by LC-MS/MS (Dr. Janáky,
University of Szeged). Bovine RACK1 (Gene: GNB2L1, Ac-
cession number: P63243) was identified using Swissprot and
Uniprot TREMBL database. This result was confirmed by
Western blot analysis of the pull-down samples using anti-
RACK1 antibody (Figure 1A). Specific band of RACK1 can
be seen in the total cell lysate (positive control) and in the
GST-TIMAP sample which was incubated with the cell lys-
ate, however, no RACK1 signal was detectable in the two
negative control samples suggesting a specific interaction
between TIMAP and RACK1.
Immunoprecipitation experiments were utilized to verify
the interaction of the endogenous proteins in endothelial
cells. RACK1 was shown to be present in the immunopre-
cipitate (IP) of TIMAP and vice versa, TIMAP co-
immunoprecipitated with RACK1 (Figure 1B).
Since we have shown earlier that TIMAP has a strong
interaction with PP1cδ [4,5], the presence of PP1cδ in the
TIMAP-RACK1 complexes were also examined. As it was
expected, the phosphatase was present in both the RACK1
and the TIMAP IP complexes (Figure 1C). To test whether
RACK1 binds PP1c directly without the attendance of
TIMAP, immunoprecipitation was made with RACK1 anti-
body from HeLa cells that do not express endogenous
TIMAP [3]. No interaction was detected between RACK1
and PP1cδ in HeLa cells (Figure 1C), therefore one may
conclude that RACK1 interacts with PP1cδ via TIMAP. To
further verify this result, RACK1 was immunoprecipitated
from control, non-siRNA and TIMAP specific siRNA
transfected EC. PP1cδ was not detected in the RACK1 IP
from TIMAP depleted cells (Figure 1D). In addition, mam-
malian constructs were created to express recombinant
wild type and truncated TIMAP. The truncated form does
not contain the PP1c binding motif, as the first 68 amino
acids are deleted; consequently it is expected not to bind
the phosphatase. HeLa were transfected with empty
Figure 1 RACK1 interacts with PP1cδ via TIMAP. (A): Bacterially expressed glutathione S-transferase (GST) and GST-tagged wild-type TIMAP
were loaded onto glutathione-Sepharose as described in Materials and Methods. After a washing step the resin samples were incubated with
BPAEC lysate (CL) or cell lysis buffer (LB). Non-binding proteins were washed out and the bound proteins were eluted with 10 mM glutathion.
Western blot probed with RACK1 specific antibody (A) of the endothelial cell lysate (CL) and the eluted fractions after the pull-down are shown.
(B,C): RACK1 or TIMAP was immunoprecipitated from lysates of BPAEC (B) and BPAEC or HeLa (C) cells as described in Materials and Methods. IP
complexes were probed for TIMAP and RACK1 (B) or PP1cδ (C). CL: cell lysate, Ø AB: control of IP from BPAEC without the addition of antibody.
(D,E): RACK1 or GFP was immunoprecipitated from non transfected (CL), non-siRNA, TIMAP specific siRNA (si TIMAP), pEGFP-C1 (GFP), pEGFP-C1
TIMAP WT (GFP-Twt) or pEGFP-C1 TIMAPΔpp1c (GFP-TΔ) transfected HeLa cell lysates. IP complexes were probed for GFP, RACK1 or PP1cδ.
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truncated TIMAP/pEGFP (GFP-TIMAP ΔPP1c) plasmids
and GFP or the endogenous RACK1 were immunoprecipi-
tated. The IP complexes were probed for RACK1, GFP and
PP1cδ (Figure 1E). Although HeLa contains PP1cδ, the
phosphatase was not present in the RACK1 IP except in
wild type TIMAP over-expressing HeLa. Moreover, PP1cδ
was not detectable with the truncated form of TIMAP in
the RACK1-GFP-TIMAP ΔPP1c complex, only in the
RACK1-GFP-TIMAP wt complex. These results imply that
PP1cδ is present in the latter complex due to its interaction
with TIMAP, but there is no direct binding between PP1cδ
and RACK1; furthermore, the presence of this phosphatase
is not a requirement for TIMAP-RACK1 interaction.Mapping the TIMAP-RACK1 interaction domains
Several deletion mutants of TIMAP were created to iden-
tify its domains concerned in the RACK1 interaction
(Figure 2A). The interface between bacterially expressed
TIMAP and endogenous RACK1 was mapped by GST
pull-down assay. Surprisingly, RACK1 was able to bind
both to the N-terminal region (TIMAP 1–290) of TIMAP
containing the nuclear localization signal (NLS), the PP1c-
binding motif and the five ANK repeats, as well as to the
C-terminal region (TIMAP 291–567) with the earlier
identified PKA and GSK3β phosphorylation sites [21] and
the C-terminal CAAX prenylation motif. The latter was
excluded as a significant region of TIMAP in the inter-
action, since the C-terminal fragment missing the CAAXbox (TIMAP 291–563) did not bind less RACK1 than
TIMAP 291–567. To further specify the interacting region
in the N-terminal section of the protein, additional shorter
recombinants were tested. When the N-terminal fragment
was shortened (TIMAP 1–165) we still could detect bind-
ing. The mutants containing only ANK4-5 and a region
with unidentified function (TIMAP 165–290) or ANK1-3
(TIMAP 67–165) did not bind to RACK1. Therefore it was
concluded that none of the ANK repeats are concerned.
The very N-terminal region of TIMAP (spanning amino
acids 1–34) do not affect the binding either. The short re-
gion of the potential NLS, however, appeared to be essential
by the comparison of the binding ability of TIMAP 35–165
and TIMAP 52–165 to endogenous RACK1 as the only dif-
ference between these two fragments is the presence or ab-
sence of the NLS motif, respectively.
The β-propeller structure of RACK1 due to its seven
WD repeats offers multiple docking sites for several inter-
actions. The association of native TIMAP to bacterially
expressed full length GST-RACK1, N-terminal (1–180) or
C-terminal (137–317) GST-RACK1 truncated forms were
studied in GST pull-down assays (Figure 2B). Our results
clearly indicate that only the N-terminal half of RACK1 is
involved in the RACK1-TIMAP interaction.Forskolin treatment attenuates the RACK1- TIMAP
interaction
RACK1 (reviewed in [22]) and TIMAP [5,21] are recog-
nized to be related to several kinases, and upon the
Figure 2 Domain mapping of TIMAP-RACK1 interaction. (A):
GST-TIMAP pull-down of endogenous RACK1. GST, recombinant GST-
TIMAP WT or additional GST-TIMAP fragments (depicted in the
upper part of panel A) were loaded onto glutathione-Sepharose as
described in Materials and Methods. The immobilized protein
samples were incubated with BPAEC lysate. Western blot of the pull-
down eluates probed with anti-RACK1 antibody is shown. CL: total
cell lysate. (B): GST-RACK1 pull-down of endogenous TIMAP. GST,
recombinant RACK1 WT or GST-RACK1 fragments (depicted in the
upper part of panel B) were tested in pull-down assay. The
immobilized samples were incubated with BPAEC lysate. Western
blot of the pull-down eluates was probed with anti-TIMAP antibody.
Representative data of at least 3 independent experiments are
shown.
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protein interactions were described. Namely, PKCs and
RACK1 mutually influence each other, but RACK1 may
participate in the cAMP/PKA pathway as well [10,12,23].
Recent results indicate that TIMAP is a target for
PKA-primed GSK-3β mediated phosphorylation on sites
Ser337 and Ser333, respectively [5,21]. Thus we next
tested the effect of the activation of PKC and PKA on the
TIMAP-RACK1 interaction challenging EC with PMA
and forskolin, respectively.The attenuative or restorative consequences of PMA or
forskolin treatment on the interaction were established
by GST pull-down assays first. Equal amounts of bacter-
ially expressed GST-TIMAP or GST-RACK1 were loaded
onto glutation Sepharose 4B as described in Materials
and Methods and untreated, forskolin or PMA chal-
lenged endothelial cell lysates were added to the resin.
Bound proteins in the eluates were analyzed by Western
blot (Figure 3A). The amount of RACK1-TIMAP com-
plex was considerably lower after the activation of the
cAMP/PKA pathway (forskolin), on the other hand,
PMA treatment of EC had no significant effect. These
findings were further strengthened with endogenous pro-
teins only, when IP complexes of RACK1 and TIMAP
drawn from EC after the same treatments were analyzed
by Western blot (Figure 3B). Truncated wild type,
S333A/S337A phosphorylation deficient, and S333D/
S337D phosphomimic mutants of a TIMAP fragment
spanning amino acids 331–567 were overexpressed in E.
coli and were utilized in pull-down experiments. Consist-
ent with the above described findings, the amount of
RACK1 bound to the phospomimic TIMAP fragment
was decreased compared to the amount of RACK1
bound to wild type TIMAP or the phosphorylation defi-
cient fragment (Additional file 2: Figure S2). These data
suggest that the phosphorylation state of TIMAP may be
an important factor in its interaction with RACK1.Activation of the cAMP/PKA pathway affects localization
of TIMAP
TIMAP localizes to the cell membrane and it is also
present in the nucleus and in the cytoplasm surrounding
the nucleus in HPAEC monolayer [4]. We investigated
whether the RACK1-TIMAP complex formation has any
effect on the subcellular localization of TIMAP. To modu-
late the interaction, HPAEC monolayers were subjected to
agents affecting the phosphorylation level of TIMAP and
the subcellular localization was detected by immunofluor-
escence studies of the monolayers or by Western blot of
subcellular fractions (Figure 4A,B). Confocal images on
Figure 4A show that the applied effectors did not change
the cytoplasmic localization of RACK1 (Figure 4A b,e,h,k).
On the other hand, upon forskolin treatment, the amount
of nuclear TIMAP decreased parallel with its more pro-
nounced appearance in the cell membrane (Figure 4A d)
compared to the untreated sample (Figure 4A a). When
cells were pretreated with a PKA inhibitor, H89, no
translocation of TIMAP to the cell membrane was
observed upon forskolin challenge, proving the involve-
ment of PKA activity (Additional file 3: Figure S3). Since
PKA phosphorylation of TIMAP on Ser337 primes its
GSK3β phosphorylation on Ser333 [5,21], AR-A014418, a
selective GSK-3β inhibitor [24], was employed alone or as
Figure 3 TIMAP-RACK1 interaction is attenuated by the cAMP/PKA pathway. (A) GST, full-length GST-TIMAP (upper part) or GST-RACK1
(lower part) were immobilized on glutathione-Sepharose and incubated with cell lysates of non treated (ctr), forskolin (50 μM for 30 min) (FRSK)
or PMA (1 μM for 30 min) treated BPAEC. The eluted proteins were tested by Western blot using anti-RACK1 and anti-TIMAP antibodies.
(B) Endogenous TIMAP or RACK1 was immunoprecipitated from BPAEC lysates after the same treatments described for panel A. IP complexes
were probed for TIMAP and RACK1. Shown are representative data of means ± SE from at least 3 independent experiments. Protein levels were
quantified by densitometric analysis. Eluted proteins were normalized against total protein levels.
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primed phosphorylation of TIMAP by GSK-3β. Without
forskolin, no TIMAP was detected in the plasma mem-
brane when GSK-3β was inhibited (Figure 4A g); also, the
effect of forskolin was strongly attenuated in the presence
of AR-A014418 (Figure 4A j). Merged images indicate co-
localization of RACK1 and TIMAP in the region of cyto-
plasm that is rather close to the nucleus in control and
GSK-3β inhibited cells cells (Figure 4A c,i,l), but co-
localization was not detectable in the cells treated exclu-
sively with forskolin (Figure 4A f).
Membrane and nuclear fractions of HPAEC were iso-
lated by cell fractionation as described in Materials and
Methods and the amount of TIMAP in the fractions was
detected by Western blot (Figure 4B). Parallel with the
results of the immunofluorescent staining, the amount of
TIMAP increased in the membrane fraction after forsko-
lin, but it was significantly lowered in the presence of
GSK-3β inhibitor compared to the control. Forskolin chal-
lenge in GSK-3β inhibited cells caused significant increase
in the TIMAP level in the membrane fraction compared
to the extremely faint signal found in the same fraction of
cells treated only with the kinase inhibitor. Furthermore,
Western blot analysis of the nuclear fractions, as expected,
demonstrated opposite trends for the changes. The least
amount of TIMAP was detected in the nuclear fraction of
the forskolin treated cells, while inhibition of GSK-3β
caused a large increase, however, forskolin significantly
moderated this effect of the inhibitor.
There was no significant change in the amount of
RACK1 in TIMAP IP of GSK-3β inhibited cells compared
to control. As expected, less RACK1 was associated toTIMAP after forskolin challenge, but no effect of forskolin
was detectable after AR-A014418 pretreatment of EC
(Figure 4C). These results suggest that interaction of
TIMAP with RACK1 may exist in the cytoplasm of EC
and it is affected by double phosphorylation (PKA and
GSK-3β) of TIMAP.Effect of RACK1 depletion on TIMAP
RACK1 was depleted in HPAEC cells using silencing RNA
duplexes specific for RACK1 (GNB2L1). The efficiency of
silencing was confirmed both at mRNA and protein level
of RACK1 by RT-PCR and Western blot (Figure 5A,B).
We detected about 70-80% and 50% decrease in the
mRNA and protein level of RACK1, respectively, in the
depleted cells compared to the control or non silencing
RNA transfected cells. Primers for B55, regulatory subunit
of protein phosphatase 2A, were used as endogenous con-
trol of RT-PCR. In the same set of experiments the mRNA
and protein level of TIMAP were evaluated as well; inter-
estingly, both increased in the RACK1 depleted HPAEC
(Figure 5A,B). This observation may suggest that RACK1
could be involved in the regulation of TIMAP transcrip-
tion, but elaboration of this assumption would require fur-
ther examination.
Immunofluorescent staining and Western blot analysis
of membrane fraction of RACK1 siRNA transfected
HPAEC revealed loss of TIMAP in the plasma membrane
(Figure 5C,D). This offers another plausible interpretation
of the increased amount of TIMAP, namely, RACK1
silenced cells simply try to compensate for the lowered
membrane localized TIMAP.
Figure 4 GSK3β inhibitor results in loss of membrane localized TIMAP. (A) Immunofluorescence staining of confluent HPAEC without (a-c)
(CTR), or with various treatments as follows: 50 μM forskolin (FRSK) for 30 min (d-f); 20 μM GSK3β inhibitor, AR-A014418, (GSK3 inh) for 4 hrs (g-i);
or 20 μM GSK3β inhibitor for 4 hrs followed by 50 μM forskolin for 30 min (j-l) using anti-TIMAP (a,d,g,j: green) and anti-RACK1 (b,e,h,k: red)
primary antibodies was performed. Representative data of at least three independent experiments are shown. Scale bars: 100 μm. (B) Subcellular
fractionations of HPAEC cells after the same set of treatments as listed in panel (A) were made as described in Materials and Methods. The
fractions were analyzed with anti-TIMAP, anti-CD31 as membrane, anti-lamin A/C as nuclear and anti-β-tubulin (not shown) as cytoplasmic marker
antibody. Shown are representative data of at least 3 independent experiments. Quantitative analysis of TIMAP signals is also shown. CD31 or
lamin A/C bands were used for protein level normalization. The results are presented as means ± SE from 3 independent experiments. Statistical
analysis was done with Student’s t-test. Significant changes are indicated by asterisks; * (P < 0.05), ** (P < 0.01), or *** (P < 0.001). (C) TIMAP was
immunoprecipitated from HPAEC after the same set of treatments as listed in panel (A). Total cell lysates and the IP complexes were probed for
TIMAP and RACK1. Additional bands in IP samples correspond to IgG.
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monolayers could be affected by RACK1 depletion as a
consequence of loss of TIMAP in the plasma membrane.
Endothelial barrier formation (attachment and spreading
of EC) of control and RACK1 depleted HPAEC were fol-
lowed by ECIS measurement (Figure 6A). The number of
control and siRNA transfected cells inoculated in ECIS
wells was identical; also there was no notable difference in
the cell density of the samples and no dead cells were
observed in the wells after the ECIS measurements. The
impedance values measured at 1 h after the start of the
measurement were significantly lower for the RACK1
silenced sample. During the 20 hours of the experiment,
this difference became more pronounced, implying that the
formation of endothelial barrier was damaged in the ab-
sence of RACK1. In addition, the effect of forskolin andsphingosin 1-phosphate, two barrier enhancing ago-
nists, was strongly attenuated in RACK1 depleted EC
(Figure 6B,C).
RACK1 aids farnesylation/membrane transport of TIMAP
Since co-localization of TIMAP and RACK1 was not
detected in our previous experiments in the cell membrane,
we could exclude that RACK1 would be directly involved
in the transport of TIMAP. Yet, we hypothesized that the
prenylation of TIMAP leading to its movement to the
plasma membrane may require the anchoring property of
RACK1. Indeed, we detected interaction of farnesyl trans-
ferase with RACK1 in pull-down assay, the binding region
in RACK1 is in the N-terminal WD1-4 region (Figure 7A).
Most importantly, TIMAP and farnesyl transferase co-
immunoprecipitated from HPAEC with normal RACK1
Figure 5 RACK1 depletion modulates mRNA and protein levels of TIMAP and affects the membrane localization of TIMAP. (A) HPAEC
grown on 6-well plate was transfected with small interfering RNA (siRNA) as described in Materials and Methods. Total RNA was isolated from
non transfected (ctr), non silencing RNA, or RACK1 specific siRNA (siGBN2L1) transfected cells and analyzed by RT-PCR using specific primer pairs
for RACK1, PP2A B (irrelevant control) or TIMAP. (B) Western blot analysis of non transfected (ctr), non silencing RNA, or siGBN2L1 transfected cells
using RACK1, TIMAP and actin specific antibodies. Actin was tested as loading control. The amount of RACK1 or TIMAP signal was expressed as
ratio of RACK1/TIMAP:β-actin signal density. The error bars correspond to SE from 3 independent transfections. Statistical analysis was done with
Student’s t-test. Significant changes are indicated by asterisks; ** (P < 0.01), or *** (P < 0.001). (C) Immunofluorescence staining of confluent non
transfected (ctr) (a-c), non silencing RNA (d-f) or siGBN2L1 treated (g-i) HPAEC using anti-TIMAP (a,d,g: green) and anti-RACK1 (b,e,h: red) primary
antibodies is presented. Scale bars: 100 μm. (D) Membrane fractions of non transfected (ctr), non silencing RNA or siGBN2L1 transfected HPAEC
were isolated as described in Materials and Methods. Total cell lysate (CL) was also loaded as control. The fractions were analyzed with anti-TIMAP
and anti-CD31 antibodies. Shown are representative data of at least 3 independent experiments.
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suggesting a pivotal role of RACK1 in TIMAP prenylation.
Discussion
Vascular EC barrier integrity is critical to tissue and
organ function [1,25]. The uniquely high expression of
TIMAP protein in endothelial cells [3] implies its signifi-
cance in fundamental activities of this cell type. In fact,
our previous findings indicated its involvement in theregulation of endothelial cell barrier function [4]. Still,
only a few of its protein interactions were identified
[5-7]. In a search for further partners of TIMAP we
recognized and proved by different methods that
TIMAP binds the adaptor protein, RACK1. This work
was focused on the characterization of this novel
interaction.
RACK1 is known as a scaffolding protein which belongs
to the WD-repeat containing proteins. It seems that
Figure 6 RACK1 depletion attenuates EC barrier function. Non
transfected (ctr), non silencing or RACK1 specific silencing RNA
transfected HPAEC were plated (5 x 105 cells/well) onto two 8W10E
arrays 48 h post-transfection. (A): The initial resistance values at the
beginning of the measurement were about 300 Ω and the
impedance was measured for 20 hrs after the seeding. (B,C): After
overnight incubation and basal TER monitoring (900–1200 Ω),
HPAEC monolayers were treated with 50 μM forskolin (B) or 1 μM
sphingosine 1-phosphate (S1P) (C). Relative resistances that were
detected at the time of maximal TER increase of forskolin/S1P
treated cells are shown for each sample. The results are presented as
means ± SEM at least of four chambers for each treatment.
Figure 7 TIMAP interacts with farnesyl transferase via RACK1.
(A) GST-RACK1 pull-down of endogenous farnesyl transferase (FNTA).
GST, recombinant RACK1 WT or GST-RACK1 fragments were tested
in pull-down assay. The immobilized samples were incubated with
BPAEC lysate. Western blot of the pull-down eluates was probed
with anti-FNTA antibody. (B) TIMAP or FNTA was
immunoprecipitated from non transfected (ctr), non silencing RNA
or siGBN2L1 transfected HPAEC. Total cell lysates and the IP
complexes were probed for TIMAP and FNTA. Additional bands in IP
samples correspond to IgG.
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ture in its binding partners. Among the RACK1 interact-
ing proteins some contain Src homology (SH2) domains
[14], pleckstrin homology (PH) domains like dynamin
[23,26], C2 and V5 domains in PKCs [27,28] or PDZ
domains [29]; but there is also example for a whole spe-
cific structural conformation requirement on the partner’s
side [30]. Our results indicate that RACK1 binds to the
NLS region at the N-terminal of TIMAP, but there is/are
further association site(s) within the C-terminal half re-
gion of TIMAP suggesting a more complex surface for the
interaction. It should be noted that the PKA/GSK-3β
phosphorylation sites, Ser337/333 of TIMAP are presentin this region. Moreover, we showed that the site/region in
RACK1 responsible for TIMAP binding is within the
N-terminal half (WD 1–4) of the protein. RACK1 forms
homodimers via the fourth WD repeat [31], therefore both
the N- and C-terminal mutants tested were designed to
contain WD 4 as described by others [32]. Thus the bind-
ing region can be further narrowed to WD 1–3, but eluci-
dation of the exact binding sites in TIMAP and RACK1
requires additional research. Another PP1 related protein,
CPI17 (PKC potentiated PP1 inhibitor), was recognized as
binding partner of RACK1 by yeast two-hybrid screening
[33]. Interestingly, binding of the dimer form (catalytic
and scaffolding subunit) of PP2A, another major Ser/Thr
protein phosphatase, was shown to a C-terminal WD re-
peat in RACK1 [32,34]. The mutual or exclusive binding
of the two subunits of PP2A was not resolved. We found
that PP1cδ is present in the RACK1-TIMAP complex as
TIMAP is its regulatory/targeting subunit, but does not
bind directly to RACK1.
Although RACK1 and PKC are intimately related to
each other (for review see [22]), that seems irrelevant in
the TIMAP-RACK1 relation, as PKC activation of EC
did not change their binding. On the other hand, activa-
tion of the cAMP/PKA pathway had significant effect not
only on the interaction, but also on the localization of
TIMAP. The second messenger cAMP is known as endo-
thelial barrier stabilizer [35,36]. Upon cAMP/PKA
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the plasma membrane and its translocation from the nu-
cleus. Since parallel translocation of RACK1 did not hap-
pen from the cytoplasm of EC either to the membrane or
to the nucleus, this suggests that separate signaling path-
ways regulating nuclear export and membrane traffic of
TIMAP could be initiated simultaneously.
RACK1 is connected to the cAMP/PKA signaling path-
way through its interaction with cAMP phosphodiesterases
[12,37]. Similar to our results, in hippocampal neurons dis-
sociation of RACK1 from its binding partner, Fyn kinase,
occurs upon activation of the PKA pathway [38]. RACK1
translocated to the nucleus in glioma and neuroblastoma
cell lines upon PKA activation by forskolin [39] to mediate
the expression of a brain-derived neurotrophic factor. In
contrast, no translocation of RACK1 upon forskolin treat-
ment of EC was observed in our experiments. However, it
was revealed recently that phosphorylation by PKA or se-
quential phosphorylation by PKA and GSK-3β only slightly
modulated the binding of TIMAP to PP1cδ [5]. The dis-
sociation constant of the complex was about the same,
only the rate of dissociation decreased to a small extent.
In vitro phosphatase assays indicated that double
phosphorylated form of TIMAP allowed PP1c activity
toward phospho-moesin substrate, but mono- or non-
phosphorylated form of TIMAP inhibited the phosphatase.
PKA/GSK-3β phosphorylation sites, Ser337/333 of TIMAP
are present in the C-terminal region which was shown to
bind RACK1, thus the phosphorylation of these side chains
may affect not only the regulatory effect of TIMAP on
PP1cδ, but the binding of TIMAP to RACK1 as well. The
phosphorylation may directly impair the connection by in-
ducing conformation change of TIMAP, or may initiate
interactions with other binding partners leading to the loss
of RACK1-TIMAP complex. Our results clearly demon-
strate that significant loss in TIMAP-RACK1 complex fol-
lows PKA primed GSK-3β phosphorylation of TIMAP.
On the contrary, when the TIMAP-RACK1 interaction
was diminished by depletion of RACK1, TIMAP was not
found in the plasma membrane of the silenced cells sug-
gesting a pivotal role of RACK1 in prenylation/membrane
localization of TIMAP. Significance of RACK1 in mem-
brane localization of a Vang protein was also recognized
by RACK1 knockdown recently [40]. Prenylation of
TIMAP at the C-terminal CAAX box [3] by farnesyl
transferase [41] is required for its membrane localization.
Eventually, deficiency of membrane anchored TIMAP
may be the result of the lack of its prenylation. Our results
indicated that both TIMAP and farnesyl transferase bind
to the N-terminal half of RACK1 and the interaction be-
tween TIMAP and farnesyl transferase was diminished in
RACK1 depleted cells. These confirm the assumption of
RACK1 being the anchoring surface for prenylation of
TIMAP. Since TIMAP is involved in the regulation of ECbarrier function [4], RACK1 should also be regarded as a
participant in maintaining barrier integrity, through the
regulation of TIMAP prenylation. The pulmonary vascular
endothelium functions as a semi-selective barrier between
blood and surrounding tissues and controls biological pro-
cesses such as protein and fluid transport or inflammation.
Endothelial barrier dysfunction is the primary cause of
vascular leak and pulmonary edema in sepsis and is an es-
sential component of angiogenesis, tumor metastasis, and
atherosclerosis. Therefore, the maintenance of vascular EC
barrier integrity may have profound clinical importance. In
agreement with the conclusion that RACK1 is involved in
the maintenance of barrier integrity, we found decelerated
barrier formation in RACK1 depleted EC. Consistent with
this, it was shown by others that RACK1 regulates cell ad-
hesion [42], moreover, silencing of RACK1 inhibited cell
proliferation and decreased migration and adhesion cap-
ability of carcinoma cells [43]. A recent paper [44]
described the involvement of RACK1 in Gβγ-mediated
adherens junction assembly in EC. They studied the func-
tion of Gβγ in re-annealing of adherens junctions after
thrombin challenge/PAR activation. RACK1, normally
bond to Gβγ, is released after thrombin and that triggers
Fyn activation via the focal adhesion kinase. In RACK1
depleted cells, they detected slower recovery of TER after
thrombin. Our TER measurement with thrombin treated
RACK1 depleted cells showed the same result (not shown).
Still, the positive effect of cAMP/PKA activation (forskolin
treatment) on TER was significantly attenuated in RACK1
silenced EC. Moreover, sphingosin-1-phosphate, a well-
known vascular stabilizer [45,46], had also failed to in-
crease TER in RACK1 depleted cells. It seems, that RACK1
may be involved in multiple signaling pathways concerned
in EC barrier regulation.Conclusions
The anchoring protein RACK1 was recognized as a new
TIMAP binding partner in EC and the regions of the
interacting surfaces were identified. The interaction is
transient, our results indicated that cAMP/PKA activation
affected their binding and evoked a change in localization
of TIMAP from the nucleus to the cell membrane. We
propose that the phosphorylation of TIMAP pool bound
to RACK1 in the cytosol may initiate a conformation
change of TIMAP which facilitates its prenylation and
translocation to the cell membrane. The cytosolic pool of
TIMAP is “re-filled” from the nucleus, gets prenylated as
well and moves to the plasma membrane (Figure 8).
RACK1 supports this process by providing a simultaneous
anchoring surface for TIMAP and farnesyl transferase.
This ensures prenylation and subsequently membrane
transport of TIMAP, where it may fulfill its barrier main-
taining role as a PP1 regulatory protein.
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Reagents
Materials were obtained from the following vendors: paraf-
ormaldehyde, dimethylsulfoxide, bovine serum albumin, for-
skolin, anti-FNTA antibody, AR-A014418, sphingosine 1-
phosphate: Sigma (St Louis, MO), custom-made rabbit
polyclonal anti-TIMAP antipeptide (NGDIRETRTDQENK)
antibody: Zymed laboratories (San Francisco, CA), a kind
gift from Dr. A. Verin, Georgia Health Science University,
Augusta, GA; anti-RACK1 antibody: BD Transduction
Laboratories (Heidelberg, Germany); anti-rabbit IgG HRP-
linked and anti-mouse IgG HRP-linked secondary anti-
bodies, CD31(PECAM-1) antibody: Cell Signaling Technol-
ogy, Inc. (Beverly, MA); anti-PP1 delta antibody: Upstate
Biotechnology (Lake Placid, NY); anti-lamin A/C (H-110)
antibody: Santa Cruz Biotechnology, Inc. (Santa Cruz, CA);
mouse anti-GFP antibody: Invitrogen CorporationFigure 8 Proposed model for prenylation and redistribution of TIMAP
non-phosphorylated TIMAP is localized in the nucleus, also in the cytosol b
is at the cell membrane. (B,C) Upon PKA/GSK3β activation TIMAP in the RA
C-terminal CAAX box becomes accessible for prenylation by farnesyl transf
the cell membrane and RACK1 gets refilled with TIMAP from the nuclear p
complex becomes low. Based on our previous result [5] PP1c is shown in c
different phosphatase activities of the complex. Representation of MYPT3 in(Carlsbad, CA); rabbit anti GFP: Merck Millipore (Billerica,
MA); Alexa 488-, Alexa 594-conjugated secondary anti-
bodies and ProLong Gold Antifade medium with DAPI:
Molecular Probes (Eugene, OR), restriction enzymes, T4
DNA ligase: Thermo Scientific, Inc. (Vantaa, Finland); Pro-
tease Inhibitor Cocktail Set III: EMD Biosciences (San
Diego, CA); pEGFP-C1, pGEX-4 T-2 and pGEX-4 T-3 vec-
tors: Clontech Laboratories, Inc. (Mountain View, CA).
Substances for cell culturing were from PAA (Austria). All
other chemicals were obtained from Sigma (St Louis, MO).Cell cultures
Human Pulmonary Artery Endothelial Cells (HPAEC)
(catalogue No: CC-2530) were obtained frozen at passage
3 (Lonza Group Ltd, Switzerland) and were cultured in
EGM-2 Endothelial Cell Growth Medium-2 supplementedupon cAMP/PKA activation. (A) In EC monolayer
ound to RACK1, while prenylated and phosphorylated form of TIMAP
CK1 complex is phosphorylated resulting in conformation change, the
erase (FT) bound also to RACK1. The prenylated TIMAP relocalizes to
ool. When that pool is exhausted, the amount of RACK1-TIMAP
omplex with both non- and phosphorylated TIMAP, colors indicate
[47] was used in the proposed conformational changes of TIMAP.
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Cells were utilized at passages 5–7. Bovine pulmonary ar-
tery endothelial cells (BPAEC) (culture line-CCL 209)
were obtained frozen at passage 8 (American Type Tissue
Culture Collection, Rockville, MD), and were utilized at
passages 15–20. Cells were maintained at 37°C in a hu-
midified atmosphere of 5% CO2 and 95% air in MEM sup-
plemented with 10% (v/v) heat inactivated fetal bovine
serum, 1% sodium pyruvate, 0.1 mM MEM non-essential
amino acids solution. HeLa cells (catalogue No: 93021013)
were obtained frozen at passage 4 (ECACC, Salisbury,
UK) and maintained in DMEM supplemented with 10%
(v/v) FBS, 2 mM glutamine and 0.1 mM non-essential
amino acids solution.
SDS-PAGE and LC-MS/MS analysis
Proteins were resolved by SDS-PAGE and stained with
Blue Silver solution [48]. Liquid Chromatography with
Tandem Mass Spectrometry Detection was performed by
Dr. Tamás Janáky at the University of Szeged, Faculty of
Medicine, Department of Medical Chemistry. All samples
were washed with 0.1 M NH4HCO3 and acetonitrile then
digested with trypsin for 16 hours. The samples were dis-
solved in 0.1 M formic acid/H2O and aliquots (15 μL)
were injected onto Waters NanoAcquity UPLC-QTOF
trap. The retained materials were placed onto Waters BEH
C18 trap (1.7 μm, 250×0.075 mm) and eluted (350 nL/
min) with an increasing concentration of 0.1% formic acid/
acetonitrile. Eluted peptides were analyzed by Data
Dependent Aqusition and the three most abundant precur-
sor ions were selected for MS/MS. Data were evaluated
with ProteinLynx GlobalServer 2.4 software and Mascot
2.04 data browser.
Preparation of TIMAP and RACK1 constructs
The coding region of wild-type TIMAP (NM_015568) was
amplified by RT-PCR as described earlier [4]. Additional
bacterial TIMAP constructs (the corresponding peptide
regions are identified by the number of N- and C-terminal
amino acids) were derived from the bacterial full length
TIMAP construct and cloned into pGEX-4 T-3 vector
using the following primer pairs. TIMAP 1–290: 5’- TGGG
ATCCATGGCCAGTCACGTGG-3’, 5’-AACTCGAGCTA
TGCACTGAGACTAGCTC-3’;TIMAP 1–165: 5’-TGGG
ATCCATGGCCAGTCACGTGG-3’, 5’- TTCTCGAGCTA
CGAGTTGACAGCAGGCA-3’; TIMAP 165–290: 5’- TA
GGATCCGATGGGAACATGCCATATGA-3’, 5’- AACTC
GAGCTATGCACTGAGACTAGCTC-3’; TIMAP 35–165:
5’- TGGGATCCAAGAAATGGGCACAGTACG-3’; 5’-
TTCTCGAGCTACGAGTTGACAGCAGGCA-3’; TIMAP
52–165: 5’- TTGGATCCGAGCGGAAGCGCAGCA-3’, 5’-
TTCTCGAGCTACGAGTTGACAGCAGGCA-3’; TIMAP
67–165: 5’- TTGGATCCGAGGCCAGCGTGGC-3’, 5’- T
TCTCGAGCTACGAGTTGACAGCAGGCA-3’; TIMAP291–567: 5’- TTGGATCCAGGACATCCATGGATGAGA
TG-3’, 5’- CGCTCGAGTCCTAGGAGATACGGCAAC-3’;
TIMAP 291–564: 5’- TTGGATCCAGGACATCCATGGA
TGAGATG-3’, 5’- TTCTCGAGCTAACAGCCATGCACC
TTCT-3’; TIMAP 331–567: 5’-TAGGATCCTCCTTGA
GCCGGAGGACCTCCAG-3’, 5’- CGCTCGAGTCCTAGG
AGATACGGCAAC-3’; TIMAP 331–567 S333A/S337A: 5’-
TAGGATCCTCCTTGGCTCGGAGGACCGCTAG-3’, 5’-
CGCTCGAGTCCTAGGAGATACGGCAAC-3’; TIMAP
331–567 S333D/S337D: 5’-TAGGATCCTCCTTGGACCG
GAGGACCGACAG-3’, 5’- CGCTCGAGTCCTAGGAGA
TACGGCAAC-3’. Mammalian wild type and truncated
form (does not contain the first 68 amino acids, including
the PP1c binding motif) of TIMAP constructs were ampli-
fied using the following primer pairs and cloned into
pEGFP-C1 vector. TIMAP WT: 5’-GGCTCGAGCTATG
GCCAGTCACGTGGACCT-3’, 5’-CGCGGATCCCTAGG
AGATACGGCAACAGCC-3’; TIMAP Δpp1c: 5’-GGCTC
GAGCTATGAGCGTGGCCCTGCTGG-3’, 5’-CGCGGAT
CCCTAGGAGATACGGCAACAGCC-3’. Human cDNA
prepared from HeLa cells by RT employing oligo dT primer
was used for RACK1 (NM_006098.4) amplification with
the following primers: RACK1 WT: 5’-GTGTCGACTATG
ACTGAGCAGATGACCCT-3’, 5’-AAGCGGCCGCCTAG
CGTGTGCCAATGGT-3’; RACK1 1–180: 5’-GTGTCG
ACTATGACTGAGCAGATGACCCT-3’, 5’- AAGCGGCC
GCCTAAGCCAGGTTCCATACCT-3’; RACK1 137–317:
5’-GTGTCGACTGTGTGCAAATACACTGTCCAG-3’, 5’-
AAGCGGCCGCCTAGCGTGTGCCAATGGT-3’. All pri-
mers were synthesized by Integrated DNA Technologies
(Coralville, IA). The DNA sequences of the constructs were
confirmed by sequencing (Clinical Genomics Center,
MHSC, RCMM, University of Debrecen).Bacterial expression and GST pull-down assay
Escherichia coli BL21 (DE3) transformed with pGEX-4 T-3
containing glutathione S-transferase (GST), pGEX-4 T3
containing TIMAP mutants or pGEX-4 T-2 containing
RACK1 constructs were induced with 1 mM IPTG and
grown at room temperature (RT) with shaking for 3 h.
Cells were harvested by centrifugation, sonicated in lysis
buffer (50 mM Tris–HCl (pH 7.5), 0.1% Tween 20, 0.2% 2-
mercaptoethanol, protease inhibitors) and proteins were
isolated by affinity chromatography on glutathione Sephar-
ose 4B (GE Healthcare, Piscataway, NJ) according to the
manufacturer’s protocol. BPAEC grown in 100-mm culture
flasks were washed twice with 1X ice-cold PBS, scraped,
and lysed in 600 μl lysis buffer. The lysates were incubated
with GST or different GST-fused proteins coupled to
glutathione Sepharose beads for 4 h at 4°C. The beads were
washed three times with 1X PBS then the GST fusion pro-
teins were eluted with 10 mM glutathione and were tested
for interacting proteins by SDS-PAGE and Western blot.
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HeLa cells were transfected with pEGFP-C1, pEGFP-C1
TIMAP WT or pEGFP-C1 TIMAP Δpp1c plasmids using
Lipofectamine 2000 transfection reagents (Invitrogen Cor-
poration (Carlsbad, CA), according to the manufacturer’s
instructions. After 24 hours cells were washed with PBS and
used for immunoprecipitation.
RACK1 (GNB2L1) and TIMAP (PPP1R16B) were
silenced using 50 nM ON-TARGETplus SMARTpool
siRNA (L-006876-00-0 HumanGNB2L1 and L-004065-00-0
HumanPP1R16B, respectively, Dharmacon) in complex with
DharmaFECT-4 transfection reagent (Dharmacon) in
serum-free medium. ON-TARGETplus siCONTROL non-
targeting pool (D-001810-10-01-05; Dharmacon) was used
as an irrelevant control. After 6 h the medium was changed
to complete medium. Cells were further incubated for
48 hours.RT-PCR
Confirmation of RACK1 silencing was performed by RT-
PCR. Total RNA was extracted from HPAEC using ZR
RNA MicroPrep™ (Zymo Research Corporation, CA).
cDNA was synthesized from 2 μg of total RNA using
oligo-dT primer and M-MLV reverse transcriptase
(Promega Corporation, USA). For PCR PhusionW High-
Fidelity DNA Polymerase (Thermo Scientific, Inc.,
Vantaa, Finland) was used. To monitor the amount of
RACK1, TIMAP and PP2A B55 RNA, the following pri-
mers were used: RACK1 (GNB2L1): 5’-GTGTCGACTA
TGACTGAGCAGATGACCCT-3’, 5’-AAGCGGCCGCC
TAGCGTGTGCCAATGGT-3’, TIMAP (PPP1RB16): 5’-
TGGGATCCGAGAATAAGGACCCTAACC-3’, 5’- CGC
TCGAGTCCTAGGAGATACGGCAAC-3’, PP2A B55
(PPP2R2A): 5’-CAGCACCTTCCAGAGCCA-3’, 5’-GG
CAGATGCCCTCATGTC-3’.Immunofluorescence and microscopy
Cells were grown on glass coverslips, washed once with
1X PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4,
1.47 mM KH2PO4, pH 7.4) and fixed with 3.7% parafor-
maldehyde in 1X PBS for 10 min at RT. Between each
step, the cells were rinsed three times with 1X PBS. The
cells were permeabilized with 0.5% Triton X-100 in PBS
at RT for 15 min, blocked with 2% BSA in PBS for
30 min at RT, and incubated with primary, then with
secondary antibodies diluted in blocking solution for 1 h
at RT. Cover slips were rinsed and mounted in ProLong
Gold Antifade medium. Confocal images were acquired
with an Olympus Fluoview FV1000 confocal microscope
using UPLSAPO 60× 1.35 NA oil immersion objective
on an inverted microscope (Olympus IX81) at 25°C.
Images were processed using FV10-ASW v1.5 software
and further processed with PhotoShop Imaging software.Nonspecific binding of the secondary antibodies was
checked in control experiments (not shown).Immunoprecipitation
BPAEC were grown in 100-mm tissue culture dishes, rinsed
three times with 1x PBS and then collected and lysed with
600 μl of immunoprecipitation (IP) buffer (20 mM Tris
HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM sodium
vanadate, 1% Nonidet P-40) containing protease inhibitors.
The lysates were centrifuged with 10,000 g for 15 min at
4°C. To avoid nonspecific binding, the supernatants were
precleared with 50 μl of protein G Sepharose (GE Health-
care, Piscataway, NJ) at 4°C for 3 h with end-over-end rota-
tion. Protein G Sepharose was removed by centrifugation at
4°C for 10 min, and the supernatant was incubated with the
appropriate volume of antibody at 4°C for 1 h and then
with 50 μl of fresh protein G Sepharose at 4°C overnight
with gentle rotation. The resin was washed three times with
300 μl of IP buffer and then resuspended in 150 μl of 1X
SDS sample buffer, boiled, and microcentrifuged for 5 min-
utes. The supernatant was further analyzed by Western
blot.Subcellular fractionation
Membrane fractions were isolated using ProteoJET™
Membrane Protein Extraction Kit and nuclear fractions
were extracted by ProteoJET™ Cytoplasmic and Nuclear
Protein Extraction Kit (Thermo Scientific, Inc.,Vantaa,
Finland) according to the manufacturer’s protocol. The ef-
ficiency of fractionation was analyzed by immunoblotting
using CD31 antibody as a membrane marker, lamin A/C
antibody as a nuclear marker and β-tubulin antibody (not
shown) as a cytoplasmic marker.
Western blotting
Protein samples were separated by SDS-PAGE and trans-
ferred to 0.45 μm pore sized Hybond ECL Nitrocellulose
Membrane (GE Healthcare, Piscataway, NJ). Western blots
were imaged using an Alpha Innotech FluorChemW FC2
Imager or Kodak Medical X-ray Developer.
ECIS measurements
ECIS (Electric cell-substrate impedance sensing) model
Zθ, Applied BioPhysics Inc. (Troy, NY) was used to
monitor transendothelial electric resistance [49] of con-
trol or transfected cells seeded on type 8W10E arrays.
Statistical analysis
Statistical analysis was done with Student’s t-test. Significant
changes are indicated by asterisks; * (P < 0.05), ** (P < 0.01),
or *** (P < 0.001). Densitometric analyses of immunoblots
were done by Image J software.
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Additional file 1: Figure S1. Detection of TIMAP-RACK1 interaction by
pull-down. Bacterially expressed glutathione S-transferase (GST) and GST-
tagged wild-type TIMAP were loaded onto glutathione-Sepharose as
described in Materials and Methods. After a washing step the resin
samples were incubated with BPAEC lysate (CL) or cell lysis buffer (LB).
Non-binding proteins were washed out and the bound proteins were
eluted with 10 mM glutathion. Blue silver staining of the endothelial cell
lysate (CL) and the eluted fractions after the pull-down are shown. Red
arrow points the band of a possible interacting protein (PI) appearing
only in the TIMAP sample incubated with EC cell lysate (TIMAP + CL). That
band was cut from the gel and was identified by LC-MS/MS as RACK1
which was confirmed by Western blot (Figure 1).
Additional file 2: Figure S2. Phosphomimic mutation of TIMAP
attenuates RACK1 binding. GST, recombinant GST-tagged truncated wild
type, S333A/S337A, and S333D/S337D mutants of a TIMAP fragment
(amino acids 331–567) were loaded onto glutathione-Sepharose as
described in Materials and Methods. The immobilized protein samples
were incubated with BPAEC lysate. Western blot of the pull-down eluates
probed with anti-RACK1 antibody is shown. CL: cell lysate. Representative
data of at least 3 independent experiments are shown.
Additional file 3: Figure S3. Effect of PKA inhibition on the localization
of TIMAP. Immunofluorescence staining of confluent HPAEC without
(control), or with various treatments as follows: 10 μM H89 (PKA inhibitor)
for 30 min; 50 μM forskolin for 30 min; or 10 μM H89 for 30 min followed
by 50 μM forskolin for 30 min using anti-TIMAP antibody and Texas-Red
Phalloidin. Scale bars: 100 μm.
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